Phase III KEYNOTE-177 Study of Pembrolizumab Doubles PFS in MSI-H/dMMR mCRC

Front-line therapy with pembrolizumab doubled progression-free survival versus chemotherapy in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer.

Source: CancerNetwork - May 28, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news